[go: up one dir, main page]

AR086516A1 - Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso - Google Patents

Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso

Info

Publication number
AR086516A1
AR086516A1 ARP120101804A ARP120101804A AR086516A1 AR 086516 A1 AR086516 A1 AR 086516A1 AR P120101804 A ARP120101804 A AR P120101804A AR P120101804 A ARP120101804 A AR P120101804A AR 086516 A1 AR086516 A1 AR 086516A1
Authority
AR
Argentina
Prior art keywords
cgrp
antibodies
binding fragments
epitopes
fragment
Prior art date
Application number
ARP120101804A
Other languages
English (en)
Inventor
Benjamin H Dutzar
Jens S Billgren
John A Latham
Danielle M Mitchell
Patricia Dianne Mneill
Brian Robert Kovacevich
Katie Olson
Nicole M Jason
Maria Loomis
Leon F Cristina-Garcia-Martinez
Original Assignee
Alderbio Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086516(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alderbio Holdings Llc filed Critical Alderbio Holdings Llc
Publication of AR086516A1 publication Critical patent/AR086516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos y fragmentos de los mismos con especificidad de unión al CGRP (péptido relacionado con el gen de la calcitonina). Otra forma de realización se relaciona con los anticuerpos que se describen y fragmentos de unión de los mismos, que comprenden las secuencias de los polipéptidos VH, VL y CDR que se describen en la presente y los polinucleótidos que los codifican. También se contemplan conjugados de anticuerpos anti-CGRP y sus fragmentos de unión, conjugados con una o más unidades funcionales o detectables. La solicitud también contempla métodos para obtener dichos anticuerpos anti-CGRP y sus fragmentos de unión. Otras formas de realización se refieren al uso de anticuerpos anti-CGRP y sus fragmentos de unión, para el diagnóstico, evaluación y tratamiento de enfermedades y trastornos asociados con el CGRP.Reivindicación 1: Un anticuerpo anti-CGRP humano, o un fragmento éste, caracterizado porque puede unirse específicamente a uno o más epitopes lineales o conformacionales de un CGRP humano intacto, o de un fragmento de éste, que son idénticos a los epitopes a los que pueden unirse los anticuerpos anti-CGRP humano Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13 ó Ab14, o que están superpuestos con ellos, y/o que puede competir por la unión a dichos epitopes con los anticuerpos mencionados.
ARP120101804A 2011-05-20 2012-05-21 Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso AR086516A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20

Publications (1)

Publication Number Publication Date
AR086516A1 true AR086516A1 (es) 2013-12-18

Family

ID=47175055

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP120101804A AR086516A1 (es) 2011-05-20 2012-05-21 Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso
ARP200100966A AR118605A2 (es) 2011-05-20 2020-04-06 Composiciones anti-cgrp y sus usos
ARP210102914A AR123876A2 (es) 2011-05-20 2021-10-21 Composición farmacéutica de anticuerpos anti-cgrp

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP200100966A AR118605A2 (es) 2011-05-20 2020-04-06 Composiciones anti-cgrp y sus usos
ARP210102914A AR123876A2 (es) 2011-05-20 2021-10-21 Composición farmacéutica de anticuerpos anti-cgrp

Country Status (38)

Country Link
US (10) US9745373B2 (es)
EP (5) EP3662932B1 (es)
JP (3) JP6282584B2 (es)
KR (1) KR102128627B1 (es)
CN (5) CN107602700B (es)
AP (1) AP2013007259A0 (es)
AR (3) AR086516A1 (es)
AU (3) AU2012258966C1 (es)
BR (2) BR112013029932A2 (es)
CA (3) CA3080000A1 (es)
CL (3) CL2013003336A1 (es)
CO (1) CO6870005A2 (es)
CY (2) CY1124209T1 (es)
DK (3) DK2710039T3 (es)
EA (3) EA201891284A1 (es)
ES (3) ES2873837T3 (es)
FR (1) FR22C1032I2 (es)
HR (3) HRP20190640T1 (es)
HU (4) HUE054437T2 (es)
IL (4) IL229431B (es)
LT (4) LT2710039T (es)
LU (1) LUC00270I2 (es)
MX (3) MX370749B (es)
NL (1) NL301181I2 (es)
NO (1) NO2022029I1 (es)
NZ (1) NZ733060A (es)
PE (2) PE20141787A1 (es)
PH (2) PH12013502405B1 (es)
PL (3) PL3495392T3 (es)
PT (3) PT2710039T (es)
RS (3) RS62306B1 (es)
SG (2) SG10201604040PA (es)
SI (3) SI3495392T1 (es)
SM (3) SMT201900293T1 (es)
TR (1) TR201904088T4 (es)
TW (4) TWI646111B (es)
WO (1) WO2012162243A2 (es)
ZA (1) ZA201308637B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054809A2 (en) 2005-11-14 2007-05-18 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
NZ587292A (en) 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
SMT201900293T1 (it) 2011-05-20 2019-07-11 Alderbio Holdings Llc Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
EP3508501B1 (en) 2011-05-20 2024-11-06 H. Lundbeck A/S Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
DK2709662T3 (da) 2011-05-20 2019-11-04 Alderbio Holdings Llc Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
EP3016684B1 (en) * 2013-07-03 2022-02-23 H. Lundbeck A/S Regulation of glucose metabolism using anti-cgrp antibodies
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2016168757A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
HK1258385A1 (zh) * 2015-09-24 2019-11-08 泰瓦制药国际有限公司 预防、治疗和减轻(持续性)创伤後头痛
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
CN108473567A (zh) * 2016-01-28 2018-08-31 伊莱利利公司 Cgrp抗体及其用途
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
JP7116685B2 (ja) 2016-04-15 2022-08-10 エイチ． ルンドベック アー／エス ヒト化抗ｐａｃａｐ抗体及びそれらの使用
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
KR20190067181A (ko) 2016-09-23 2019-06-14 테바 파마슈티컬스 인터내셔널 게엠베하 군발성 두통의 치료
US20190071490A1 (en) 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
JP2020517644A (ja) * 2017-04-19 2020-06-18 マンセル、ジョン 疼痛障害の治療のための組成物および方法
EP3737699A1 (en) 2018-01-12 2020-11-18 Amgen Inc. Pac1 antibodies and uses thereof
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN112040949A (zh) * 2018-02-23 2020-12-04 瑞美德生物医药科技有限公司 降钙素基因相关肽(cgrp)拮抗剂抗体
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
PE20211708A1 (es) * 2019-01-08 2021-09-01 H Lundbeck As Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES
US12371453B2 (en) 2019-02-28 2025-07-29 HLB Science Inc. Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
WO2020222892A1 (en) * 2019-05-02 2020-11-05 Alder Biopharmaceuticals, Inc. Treatment of headache using anti-cgrp antibodies
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
BR102020007149A8 (pt) * 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
KR20240049275A (ko) 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
EP4570913A1 (en) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
IT202300010371A1 (it) * 2023-05-23 2024-11-23 Alberto Chiarugi Inibitori della crescita tumorale
CN120899912A (zh) * 2024-05-07 2025-11-07 中国人民解放军军事科学院军事医学研究院 一种治疗自身免疫性疾病的方法和应用
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE134631T1 (de) * 1983-06-15 1985-12-05 Roger Kingdom Craig Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
JPH11512396A (ja) 1995-09-05 1999-10-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
EP0934068A1 (en) 1996-09-09 1999-08-11 Smithkline Beecham Corporation Compounds and methods
DK0927192T3 (da) 1996-09-10 2004-09-13 Boehringer Ingelheim Pharma Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
AU1219000A (en) 1998-10-22 2000-05-08 Regents Of The University Of California, The Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
AU4002001A (en) 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CA2471833A1 (en) 2001-11-26 2003-06-05 Protemix Corporation Limited Methods of compositions for normalizing lipid levels in mammalian tissues
SI1527100T1 (sl) 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
EP1501929B1 (de) 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
KR20050008790A (ko) 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
BR0313388A (pt) 2002-08-12 2005-07-05 Birkir Sveinsson Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2508375C (en) 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
CA2511598C (en) 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
ATE509019T1 (de) 2003-03-14 2011-05-15 Merck Sharp & Dohme Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
CA2518852A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Monocyclic anilide spirohydantoin cgrp receptor antagonists
WO2004082602A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Carboxamide spirohydantoin cgrp receptor antagonists
JP4673294B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
ATE516803T1 (de) 2003-03-14 2011-08-15 Merck Sharp & Dohme Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
AU2004229518B2 (en) 2003-04-15 2010-02-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US20060173046A1 (en) 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
DK1678314T3 (da) * 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2619856A1 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
WO2007054809A2 (en) * 2005-11-14 2007-05-18 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007061676A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
AU2007307324B2 (en) 2006-05-19 2013-08-15 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific B cells
BRPI0712492A2 (pt) 2006-06-08 2012-08-21 Boehringer Ingelheim Int uso de antagonistas de cgpr e composição farmacêutica compreendendo antagonistas de cgpr.
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
TWI617576B (zh) 2007-05-21 2018-03-11 艾爾德生物控股有限責任公司 介白素-６（ｉｌ-６）的抗體及其等之用途
CN101868477A (zh) 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
WO2009109908A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating inflammatory pain
NZ587292A (en) 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
RU2535074C2 (ru) * 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
DK2709662T3 (da) 2011-05-20 2019-11-04 Alderbio Holdings Llc Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
SMT201900293T1 (it) 2011-05-20 2019-07-11 Alderbio Holdings Llc Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
EP3508501B1 (en) 2011-05-20 2024-11-06 H. Lundbeck A/S Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
HK1258385A1 (zh) 2015-09-24 2019-11-08 泰瓦制药国际有限公司 预防、治疗和减轻(持续性)创伤後头痛
US20190071490A1 (en) * 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES
PE20211708A1 (es) 2019-01-08 2021-09-01 H Lundbeck As Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r

Also Published As

Publication number Publication date
DK3495392T3 (da) 2021-09-13
TWI685505B (zh) 2020-02-21
CN107586338A (zh) 2018-01-16
JP2019150044A (ja) 2019-09-12
SI2710039T1 (sl) 2019-05-31
IL229431B (en) 2018-10-31
TW201936642A (zh) 2019-09-16
TR201904088T4 (tr) 2019-05-21
TW201300419A (zh) 2013-01-01
US10066009B2 (en) 2018-09-04
BR122022012930B1 (pt) 2023-10-10
US20190092842A1 (en) 2019-03-28
PH12018500521A1 (en) 2019-04-15
FR22C1032I1 (fr) 2022-09-09
TWI646111B (zh) 2019-01-01
MX370749B (es) 2019-12-20
CL2018001452A1 (es) 2018-08-10
IL261927A (en) 2018-10-31
EP2710039A2 (en) 2014-03-26
AU2012258966B2 (en) 2017-03-09
HRP20211395T1 (hr) 2021-12-10
RS62306B1 (sr) 2021-09-30
US20190211085A1 (en) 2019-07-11
CA3079978A1 (en) 2012-11-29
HUE054437T2 (hu) 2021-09-28
IL268464B (en) 2020-10-29
JP2018038391A (ja) 2018-03-15
CL2017001379A1 (es) 2017-12-29
ZA201308637B (en) 2022-11-30
CN103748111A (zh) 2014-04-23
DK2710039T3 (en) 2019-04-01
KR20140042819A (ko) 2014-04-07
IL229431A0 (en) 2014-01-30
CN108373502B (zh) 2022-03-22
HUE044062T2 (hu) 2019-09-30
EA201592042A1 (ru) 2016-03-31
LUC00270I2 (es) 2025-04-25
PL3662932T3 (pl) 2021-09-06
AU2012258966C1 (en) 2022-02-03
CL2013003336A1 (es) 2014-06-06
LTC3495392I2 (es) 2024-12-10
US10214582B2 (en) 2019-02-26
US20180215813A1 (en) 2018-08-02
CN108373502A (zh) 2018-08-07
NL301181I1 (es) 2022-06-15
AU2019226231A1 (en) 2019-09-26
US11111289B2 (en) 2021-09-07
NO2022029I1 (no) 2022-07-08
CN108424452B (zh) 2021-08-03
NZ733060A (en) 2022-08-26
AR118605A2 (es) 2021-10-20
IL268464A (en) 2019-09-26
JP6282584B2 (ja) 2018-02-21
CA2836649C (en) 2020-06-23
WO2012162243A3 (en) 2013-01-17
PL2710039T3 (pl) 2019-07-31
LT2710039T (lt) 2019-04-25
MX2013013535A (es) 2015-08-20
ES2893073T3 (es) 2022-02-07
WO2012162243A2 (en) 2012-11-29
HRP20210777T1 (hr) 2021-06-25
CA3080000A1 (en) 2012-11-29
CY1124209T1 (el) 2022-05-27
CO6870005A2 (es) 2014-02-20
SG10201604040PA (en) 2016-07-28
US20210047391A1 (en) 2021-02-18
CN107586338B (zh) 2021-09-17
EP3875115A1 (en) 2021-09-08
PH12013502405B1 (en) 2018-11-07
SI3495392T1 (sl) 2021-11-30
PE20141787A1 (es) 2014-12-07
US20180215815A1 (en) 2018-08-02
EA039905B1 (ru) 2022-03-25
TW202033559A (zh) 2020-09-16
EA201301295A1 (ru) 2014-04-30
US10533048B2 (en) 2020-01-14
HRP20190640T1 (hr) 2019-05-31
NL301181I2 (nl) 2022-11-24
AU2017203890A1 (en) 2017-06-29
JP6527563B2 (ja) 2019-06-05
CA2836649A1 (en) 2012-11-29
US10189895B2 (en) 2019-01-29
IL261927B (en) 2019-11-28
KR102128627B1 (ko) 2020-06-30
US20180215814A1 (en) 2018-08-02
US20240174738A1 (en) 2024-05-30
US10208112B2 (en) 2019-02-19
AP2013007259A0 (en) 2013-11-30
PT2710039T (pt) 2019-04-23
NZ618637A (en) 2016-03-31
US20120294797A1 (en) 2012-11-22
PT3662932T (pt) 2021-05-14
JP2014517699A (ja) 2014-07-24
EP2710039A4 (en) 2014-11-19
RS61793B1 (sr) 2021-06-30
EA031065B1 (ru) 2018-11-30
US20170174754A1 (en) 2017-06-22
AR123876A2 (es) 2023-01-18
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
LT3495392T (lt) 2021-09-27
US10179809B2 (en) 2019-01-15
AU2017203890B2 (en) 2019-06-06
EP3495392B1 (en) 2021-08-18
US9745373B2 (en) 2017-08-29
SMT202100274T1 (it) 2021-07-12
NZ717570A (en) 2018-09-28
LTPA2022511I1 (es) 2022-07-11
SG194938A1 (en) 2013-12-30
AU2019226231B2 (en) 2021-06-03
CY1124515T1 (el) 2022-07-22
RS58621B1 (sr) 2019-05-31
PL3495392T3 (pl) 2021-12-13
ES2873837T3 (es) 2021-11-04
EA201891284A1 (ru) 2018-11-30
EP2710039B1 (en) 2019-01-09
BR112013029932A2 (pt) 2017-01-31
EP3662932B1 (en) 2021-04-07
PE20180502A1 (es) 2018-03-09
CN107602700B (zh) 2021-12-17
TWI692485B (zh) 2020-05-01
IL270382B (en) 2020-11-30
PH12013502405A1 (en) 2014-02-10
EP3662932A1 (en) 2020-06-10
US20180215816A1 (en) 2018-08-02
HUS2200031I1 (hu) 2022-07-28
EP4115905A1 (en) 2023-01-11
CN108424452A (zh) 2018-08-21
CN103748111B (zh) 2018-04-27
MX2019015745A (es) 2020-02-13
PT3495392T (pt) 2021-09-22
MX2019008185A (es) 2019-09-09
JP6952736B2 (ja) 2021-10-20
SMT202100526T1 (it) 2021-11-12
DK3662932T3 (da) 2021-05-17
SMT201900293T1 (it) 2019-07-11
CN107602700A (zh) 2018-01-19
EP3495392A1 (en) 2019-06-12
ES2715001T3 (es) 2019-05-31
HUE055505T2 (hu) 2021-11-29
FR22C1032I2 (fr) 2023-06-02
TWI719869B (zh) 2021-02-21
LT3662932T (lt) 2021-06-10

Similar Documents

Publication Publication Date Title
AR086516A1 (es) Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso
CO6241159A2 (es) Anticuerpos para il-6 y uso de estos
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
ECSP12011761A (es) Moléculas de anticuerpo anti-gcc y composiciones y métodos relacionados.
BRPI0519775A2 (pt) proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
BR112013033258A2 (pt) moléculas de ligação de anti-alfa sinucleína
EP3447074A3 (en) Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
MX2016006561A (es) Anticuerpo anti-calicreina-2 humanizado.
JP2014043446A5 (es)
CO6160305A2 (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
MX382398B (es) Proteinas de union a antigeno st2.
NZ701444A (en) Antibodies to matrix metalloproteinase 9
IL206641B (en) Recombinant or humanized or isolated antibody or chimeric antibody, or an antibody-binding fragment thereof that selectively binds to a new epitope of humanized amyloid a peptide, a pharmaceutical preparation containing the antibody and its use for the preparation of a pharmaceutical compound for the treatment of amyloidosis
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
MX2008009886A (es) Anticuerpos que enlazan par-2.
MX347954B (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
BR112012031501A2 (pt) anticorpos de cgrp
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
PE20120475A1 (es) Anticuerpos especificos para dkk-1
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease

Legal Events

Date Code Title Description
FG Grant, registration